By Tony Fong

NEW YORK (GenomeWeb News) – Diagnostic companies developing biomarker-based tests usually work with patient samples from subjects who already have a disease for comparison with samples taken from healthy subjects.

But leveraging a biobank that it has licensed from University College London, UK firm Abcodia is betting that samples that allow researchers to track changes in patients going back years to before the onset of disease and through the progression of disease can provide new methods of disease detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.